https://www.live-feeds.com/feed/fda-approves-drug-for-pancreatic-cancer-in-incredible-moment-for-deadly-diseaseContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-approves-drug-for-pancreatic-cancer-in-incredible-moment-for-deadly-diseasehttps://www.live-feeds.com/feed/fda-approves-drug-for-pancreatic-cancer-in-incredible-moment-for-deadly-disease#u50648Fri, 28 Aug 2026 08:15:29 +0000The FDA approved daraxonrasib, a first-of-a-kind pill from Revolution Medicines branded as Rasonque, on Wednesday to treat advanced pancreatic cancer. The drug targets the KRAS protein to block tumor growth, a mechanism that affects the majority of cases. Clinical trial data showed patients using the treatment lived a median of 13.2 months. Experts suggest this approval introduces a new era for oncology by offering a different approach to managing one of the deadliest forms of cancer and improving patient survival rates.Why it mattersPancreatic cancer is notoriously difficult to treat and has https://www.live-feeds.com/feed/fda-approves-drug-for-pancreatic-cancer-in-incredible-moment-for-deadly-diseasehttps://www.live-feeds.com/feed/fda-approves-drug-for-pancreatic-cancer-in-incredible-moment-for-deadly-disease#u49555Thu, 27 Aug 2026 05:01:15 +0000The U.S. Food and Drug Administration approved daraxonrasib, a pill developed by Revolution Medicines and branded as Rasonque, to treat advanced pancreatic cancer. The drug targets KRAS and is expected to transform care for patients facing this deadly disease. Reports indicate the treatment offers a new approach to care and has shown the ability to improve patient survival. This approval marks the beginning of a new era for KRAS therapy in oncology.Why it mattersPancreatic cancer is known as a deadly form of the disease with limited treatment options. The approval of a KRAS-targeting therapy a